Does clinically guided genetic screening improve diagnostic yield in sudden unexplained death in the young compared to standard molecular autopsy panels?
Clinically guided genetic screening improves diagnostic yield in sudden unexplained death in the young, identifying affected families missed by standard molecular autopsy panels.
Sudden death in the young is of cardiovascular origin in the majority of cases. A considerable rate of SD cases remains of unknown cause on post-mortem. Apart from channelopathies, subclinical forms of inherited structural heart diseases would appear to be implicated in SADS. Clinically guided genetic screening has a significant diagnostic yield and identifies affected families that would have been missed by the current suggested molecular autopsy panel.
Anastasakis et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: